New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod
Key Highlights
- ➤Thomas H. Jensen became Valion Bio’s Board Chair in September 2026
- ➤Entolimod secured approximately $35.6 million in non-dilutive government funding
- ➤Entolimod holds FDA Fast Track and Orphan Drug designations for ARS
- ➤Valion controls Entolimod’s supply chain through wholly owned CDMO Velocity Bioworks
- ➤Valion is exploring Entolimod’s potential in cancer supportive care
Expert Statements
Thomas H. Jensen, Chair of Valion Bio and CEO and Director of Allarity Therapeutics
“A biotech company's prospects depend equally on the promise of its drug candidate and its ability to execute”
Thomas H. Jensen, Chair of Valion Bio and CEO and Director of Allarity Therapeutics
“Having led Allarity through strategic change, I appreciate the significance of Valion's own transformation earlier this year, and I see many of the key elements for success already in place.”
Thomas H. Jensen, Chair of Valion Bio and CEO and Director of Allarity Therapeutics
“The absence of an approved treatment for gastrointestinal ARS makes Entolimod's potential especially significant”
Thomas H. Jensen, Chair of Valion Bio and CEO and Director of Allarity Therapeutics
“Longer term, I see an important opportunity in exploring whether the same molecule could address needs in cancer supportive care, where I can draw on my background in oncology diagnostics and drug development.”
Thomas H. Jensen, Chair of Valion Bio and CEO and Director of Allarity Therapeutics
“I have rarely seen a company at this stage with such a substantial scientific, clinical and operational foundation”
Thomas H. Jensen, Chair of Valion Bio and CEO and Director of Allarity Therapeutics
“Our task now is to build on it with a clear sequence of achievable milestones and disciplined allocation of resources to reach them.”
SAN ANTONIO, TX / ACCESS Newswire / October 5, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today outlined the perspectives of its new Board Chair, Thomas H. Jensen, on advancing Entolimod. Entolimod is an investigational Toll-like receptor 5 (TLR5) agonist being developed as a potential medical countermeasure for acute radiation syndrome (ARS). Jensen brings more than 20 years of biotechnology and oncology experience and is CEO and a Director of Nasdaq-listed Allarity Therapeutics, Inc.
"A biotech company's prospects depend equally on the promise of its drug candidate and its ability to execute," said Jensen. "Having led Allarity through strategic change, I appreciate the significance of Valion's own transformation earlier this year, and I see many of the key elements for success already in place."
Get started
Create a free account to read the full story.